AR065891A1 - Derivados de piridina y pirimidina como antagonistas del mglur2 - Google Patents
Derivados de piridina y pirimidina como antagonistas del mglur2Info
- Publication number
- AR065891A1 AR065891A1 ARP080101333A ARP080101333A AR065891A1 AR 065891 A1 AR065891 A1 AR 065891A1 AR P080101333 A ARP080101333 A AR P080101333A AR P080101333 A ARP080101333 A AR P080101333A AR 065891 A1 AR065891 A1 AR 065891A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- group
- hydroxy
- alkoxy
- Prior art date
Links
- 101150016175 Grm2 gene Proteins 0.000 title 1
- 102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 title 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 7
- 229910052757 nitrogen Inorganic materials 0.000 abstract 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 4
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 229910052717 sulfur Inorganic materials 0.000 abstract 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 3
- 239000001301 oxygen Chemical group 0.000 abstract 3
- 125000006413 ring segment Chemical group 0.000 abstract 3
- 239000011593 sulfur Chemical group 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 1
- 229910003827 NRaRb Inorganic materials 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- -1 wherein p is 0 or 1 Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
La presente está relacionada con los compuestos de formula (1), un proceso para la elaboracion de los mismos, su utilizacion para la preparacion de medicamentos para el tratamiento de trastornos del SNC y composiciones farmacéuticas que loscontienen. Reivindicacion 1: Un compuesto de formula (1) en el que uno de entre X o Y es N y el otro es CH, o ambos X e Y son N; Q es S, O, -CH=N- o -N=CH-; A es arilo o un heteroarilo de 5 o 6 miembros cada uno de los cuales está opcionalmentesustituido por alquilo C1-6; B es un arilo opcionalmente sustituido o un heteroarilo de 5 o 6 miembros opcionalmente sustituido, en el que los sustituyentes están seleccionados de entre el grupo que consiste en: halo, nitro, alquilo C1-6opcionalmente sustituido por hidroxi, NRaRb, en el que Ra y Rb son independientemente H, alquilo C1-6 o -(CO)-alquilo C1-6, -S-alquilo C1-6, -(SO2)-OH, -(SO2)-alquilo C1-6, -(SO2)-NRcRd, en el que Rc y Rd son independientemente: H, alquilo C1-6opcionalmente sustituido por hidroxi, haloalquilo C1-6, alcoxi C1-6, -(CO)alquilo C1-6 opcionalmente sustituido por alcoxi C1-6, -(CH2CH2O)nCHRe, en el que Re es H o CH2OH y n es 1, 2, 3, 4, 5, 6, 7, 8, 9 o 10, -(CH2)m-arilo, en el que m es 1 o 2 yel arilo está opcionalmente sustituido por halo o alcoxi C1-6, -(CH2)p-cicloalquilo C3-6, en el que p es 0 o 1, heterocicloalquilo de 5 o 6 miembros, -(SO2)-NRfRg, en el que Rf y Rg junto al átomo de nitrogeno al que están unidos, forman un anilloheterocicloalquilo de 4, 5 o 6 miembros que contiene opcionalmente otro heteroátomo seleccionado de entre nitrogeno, oxígeno, azufre o un grupo XO2, en el que dicho anillo heterocicloalquilo de 4, 5 o 6 miembros está opcionalmente sustituido por unsustituyente seleccionado de entre el grupo que consiste en: hidroxi, alquilo C1-6, alcoxi C1-6 que está opcionalmente sustituido por hidroxi y heteroariloxi de 5 o 6 miembros, NHSO2-alquilo C1-6, NHSO2-NRhRi en el que Rh y Ri son independientementeH, alquilo C1-6, -(CO)O-alquilo C1-6, o Rh y Ri junto al átomo de nitrogeno al que están unidos, forman un anillo heterocicloalquilo de 4, 5 o 6 miembros que contiene opcionalmente otro heteroátomo seleccionado de entre nitrogeno, oxígeno o azufre,en el que dicho anillo heterocicloalquilo de 4, 5 o 6 miembros está opcionalmente sustituido por alquilo C1-6, R1 es H, halogeno, alquilo C1-6 opcionalmente sustituido por hidroxi, alcoxi C1-6, haloalquilo C1-6, cicloalquilo C3-6; R2 se seleccionade entre el grupo que consiste en: ciano, halogeno, haloalquilo C1-6, alcoxi C1-6, haloalcoxi C1-6, alquilo C1-6 y cicloalquilo C3-6; o es NRjRk en el que Rj y Rk se seleccionan independientemente de entre el grupo que consiste en: H, cicloalquiloC3-8, arilo, heteroarilo que posee de 5 a 12 átomos en el anillo y alquilo C1-6 que está opcionalmente sustituido por uno o más sustituyente(s) seleccionados de entre el grupo que consiste en halogeno, hidroxi, cicloalquilo C3-8, arilo, heteroariloque posee de 5 a 12 átomos en el anillo y -NRlRm, en el que Rl y Rm son independientemente seleccionados de entre el grupo que consiste en H y alquilo C1-6; o Rl y Rm pueden formar, junto al átomo de nitrogeno al que están unidos, un grupoheterocíclico opcionalmente sustituido que comprende de 5 a 12 átomos en el anillo que contiene opcionalmente otro heteroátomo seleccionado de entre nitrogeno, oxígeno o azufre, en el que dicho grupo heterocíclico está opcionalmente sustituido poruno, dos, tres, cuatro o cinco sustituyentes seleccionados de entre el grupo que consiste en halogeno, hidroxi, alquilo C1-6 y haloalquilo C1-6; así como las sales farmacéuticamente aceptables de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07105429 | 2007-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR065891A1 true AR065891A1 (es) | 2009-07-08 |
Family
ID=39457413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101333A AR065891A1 (es) | 2007-04-02 | 2008-03-31 | Derivados de piridina y pirimidina como antagonistas del mglur2 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8012986B2 (es) |
| EP (1) | EP2142527B1 (es) |
| JP (1) | JP5303544B2 (es) |
| KR (1) | KR101143152B1 (es) |
| CN (1) | CN101641346B (es) |
| AR (1) | AR065891A1 (es) |
| AT (1) | ATE493400T1 (es) |
| AU (1) | AU2008233956B2 (es) |
| BR (1) | BRPI0809971A2 (es) |
| CA (1) | CA2681733A1 (es) |
| CL (1) | CL2008000936A1 (es) |
| DE (1) | DE602008004236D1 (es) |
| IL (1) | IL200780A (es) |
| MX (1) | MX2009010505A (es) |
| PE (1) | PE20090103A1 (es) |
| TW (1) | TW200845999A (es) |
| WO (1) | WO2008119689A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201001129A1 (ru) * | 2008-01-11 | 2011-02-28 | Новартис Аг | Пиримидины в качестве ингибиторов киназы |
| US20130137865A1 (en) | 2010-08-11 | 2013-05-30 | Taisho Pharmaceutical Co., Ltd. | Heteroaryl-pyrazole derivative |
| JP2014062047A (ja) * | 2011-01-21 | 2014-04-10 | Taisho Pharmaceutical Co Ltd | ピラゾール誘導体 |
| WO2013041652A1 (en) * | 2011-09-21 | 2013-03-28 | Cellzome Limited | Morpholino substituted urea or carbamate derivatives as mtor inhibitors |
| CA3132120C (en) * | 2012-02-08 | 2023-10-24 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| SG11201503192XA (en) | 2012-10-23 | 2015-06-29 | Hoffmann La Roche | Mglu2/3 antagonists for the treatment of autistic disorders |
| KR20160143853A (ko) | 2014-04-23 | 2016-12-14 | 에프. 호프만-라 로슈 아게 | 지적 장애의 치료를 위한 mglu2/3 길항제 |
| JP6552061B2 (ja) * | 2014-06-10 | 2019-07-31 | サンフォード−バーンハム メディカル リサーチ インスティテュート | 代謝型グルタミン酸受容体の負のアロステリックモジュレーター（ｎａｍｓ）とその使用 |
| IL264446B1 (en) | 2016-07-29 | 2024-05-01 | Pgi Drug Discovery Llc | Compounds and compositions and their use |
| JP2019523279A (ja) | 2016-07-29 | 2019-08-22 | サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | 化合物および組成物ならびにそれらの使用 |
| CN111183138A (zh) | 2017-08-02 | 2020-05-19 | 赛诺维信制药公司 | 异色满化合物以及用途 |
| CN112334457A (zh) * | 2018-06-22 | 2021-02-05 | 拜耳公司 | 制备三环化合物的方法 |
| AU2020236225A1 (en) | 2019-03-14 | 2021-09-16 | Sunovion Pharmaceuticals Inc. | Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA03007513A (es) | 2001-02-21 | 2004-07-30 | Nps Pharma Inc | Compuestos heteropoliciclicos y su uso como antagonistas del receptor metabotropico de glutamato. |
| EP1613614A2 (en) | 2003-04-03 | 2006-01-11 | Merck & Co., Inc. | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| US7393959B2 (en) * | 2003-04-04 | 2008-07-01 | Merck & Co. Inc. | Di-aryl substituted pyrrole modulators of metabotropic glutamate receptor-5 |
| US7442797B2 (en) * | 2003-11-04 | 2008-10-28 | Takasago International Corporation | Platinum complex and light emitting device |
| US20060173048A1 (en) | 2005-02-03 | 2006-08-03 | Mcarthur Silvia G | Imidazole derivatives |
| EP2001849B1 (en) | 2006-03-29 | 2014-11-26 | F. Hoffmann-La Roche AG | Pyridine and pyrimidine derivatives as mglur2 antagonists |
| US20070236568A1 (en) | 2006-04-11 | 2007-10-11 | Metke Anthony R | Method and system for communicating incident scene information |
-
2008
- 2008-03-24 US US12/053,648 patent/US8012986B2/en not_active Expired - Fee Related
- 2008-03-25 JP JP2010501476A patent/JP5303544B2/ja not_active Expired - Fee Related
- 2008-03-25 CN CN2008800096420A patent/CN101641346B/zh not_active Expired - Fee Related
- 2008-03-25 CA CA002681733A patent/CA2681733A1/en not_active Abandoned
- 2008-03-25 AT AT08718155T patent/ATE493400T1/de active
- 2008-03-25 MX MX2009010505A patent/MX2009010505A/es active IP Right Grant
- 2008-03-25 DE DE602008004236T patent/DE602008004236D1/de active Active
- 2008-03-25 BR BRPI0809971-5A2A patent/BRPI0809971A2/pt not_active IP Right Cessation
- 2008-03-25 WO PCT/EP2008/053460 patent/WO2008119689A1/en active Application Filing
- 2008-03-25 KR KR1020097020481A patent/KR101143152B1/ko not_active IP Right Cessation
- 2008-03-25 EP EP08718155A patent/EP2142527B1/en not_active Not-in-force
- 2008-03-25 AU AU2008233956A patent/AU2008233956B2/en not_active Ceased
- 2008-03-31 TW TW097111725A patent/TW200845999A/zh unknown
- 2008-03-31 AR ARP080101333A patent/AR065891A1/es unknown
- 2008-04-01 CL CL200800936A patent/CL2008000936A1/es unknown
- 2008-04-01 PE PE2008000591A patent/PE20090103A1/es not_active Application Discontinuation
-
2009
- 2009-09-07 IL IL200780A patent/IL200780A/en not_active IP Right Cessation
-
2011
- 2011-07-08 US US13/178,531 patent/US8415380B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US8012986B2 (en) | 2011-09-06 |
| AU2008233956B2 (en) | 2013-05-02 |
| JP5303544B2 (ja) | 2013-10-02 |
| CN101641346A (zh) | 2010-02-03 |
| MX2009010505A (es) | 2009-10-19 |
| JP2010524852A (ja) | 2010-07-22 |
| WO2008119689A1 (en) | 2008-10-09 |
| US20080280924A1 (en) | 2008-11-13 |
| CN101641346B (zh) | 2013-11-06 |
| EP2142527A1 (en) | 2010-01-13 |
| ATE493400T1 (de) | 2011-01-15 |
| DE602008004236D1 (de) | 2011-02-10 |
| EP2142527B1 (en) | 2010-12-29 |
| KR101143152B1 (ko) | 2012-05-08 |
| CA2681733A1 (en) | 2008-10-09 |
| AU2008233956A1 (en) | 2008-10-09 |
| KR20090117902A (ko) | 2009-11-13 |
| TW200845999A (en) | 2008-12-01 |
| BRPI0809971A2 (pt) | 2014-10-07 |
| IL200780A0 (en) | 2010-05-17 |
| US8415380B2 (en) | 2013-04-09 |
| PE20090103A1 (es) | 2009-02-13 |
| IL200780A (en) | 2013-01-31 |
| US20110263615A1 (en) | 2011-10-27 |
| CL2008000936A1 (es) | 2008-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR065891A1 (es) | Derivados de piridina y pirimidina como antagonistas del mglur2 | |
| AR060173A1 (es) | Derivados de piridina y de pirimidina como antagonistas del mglur2, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de trastornos del snc. | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR110782A1 (es) | Derivados de tirosinamida como inhibidores de rho-quinasa | |
| AR110139A1 (es) | COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR081994A1 (es) | Derivados de [1,8]naftiridina, composiciones farmaceuticas que los contienen, proceso para prepararlos y uso de los mismos para el tratamiento de enfermedades inducidas por quinasas, en particular diferentes tipos de canceres | |
| AR097008A1 (es) | Derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR058379A1 (es) | Derivados de arilpropionamida arilacrilamida arilpropinamida o arilmetilurea como inhibidores del factor xia. proceso de obtencion y composiciones farmaceuticas. | |
| AR046394A1 (es) | Derivados de quinolinas y quinazolinas, metodo de preparacion de los mismos y composiciones farmaceuticas que los contienen. | |
| AR110153A1 (es) | ÁCIDOS PROPIÓNICOS 3-SUSTITUIDOS COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR073406A1 (es) | Aminodihidrotiazinas fusionadas con tetrahidropiranos,inhibidoras de bace1 y de la produccion de abeta amiloide, composiciones farmaceuticas que las contienen y usos de las mismas para el tratamiento de enfermedades neurodegenerativas,tales como alzheimer. | |
| AR085316A1 (es) | Derivados de pirrolo[2,3-b]piridina, utiles para la modulacion de quinasas | |
| AR063318A1 (es) | Pirazoliltienopiridinas terapeuticas | |
| NO20072371L (no) | Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister | |
| AR066171A1 (es) | Derivados de nicotinamida, composiciones farmaceuticas que los contienen, metodo de preparacion de los mismos y usos en la prevencion y/o tratamiento del cancer. | |
| AR079231A1 (es) | Derivados de imidazoquinolina | |
| CO6140033A2 (es) | Amino-imidazoles y su uso como medicamento para tratar discapacidad coognotiva enfermedad de alzheimer neurodegeneracion y demencia | |
| AR068376A1 (es) | Amidas heterociclicas utiles para inhibir la via hedgehog. | |
| AR085283A1 (es) | Antagonistas de hepcidina a base de sulfonaminoquinolina | |
| AR093077A1 (es) | ANTAGONISTAS DE mGlu2/3 PARA EL TRATAMIENTO DE LOS TRASTORNOS AUTISTAS | |
| AR094684A1 (es) | Triterpenoides de c-19 modificados, con actividad inhibidora de la maduración del vih | |
| AR051295A1 (es) | Derivados de pirimidina y su uso | |
| AR083525A1 (es) | Derivados de acido picolinico sustituidos con heterociclos, metodo para prepararlos, uso de los mismos como herbicidas y composiciones herbicidas que los contienen | |
| AR066963A1 (es) | Derivados de indolinona, preparaciones farmaceuticas que los contienen y usos de los mismos para el tratamiento y/o prevencion de cancer y enfermedades inflamatorias y autoinmunes. | |
| AR097435A1 (es) | 6-alquinilpiridinas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |